

STATEMENTS FROM A PANEL CONSISTING OF: JOHN ADRIANI, M.D., DEPARTMENT OF HEALTH AND HUMAN RESOURCES, OFFICE OF CHARITY HOSPITAL AT NEW ORLEANS, LA.; MORRIS BOYNOFF, PHARMACIST, MENDOCINO, CALIF.; WILLIAM T. BEAVER, M.D., ASSOCIATE PROFESSOR OF PHARMACOLOGY AND ANESTHESIA, GEORGETOWN UNIVERSITY SCHOOLS OF MEDICINE AND DENTISTRY, WASHINGTON, D.C.; AND MICHAEL A. NEWMAN, M.D., INTERNIST, WASHINGTON, D.C.

Dr. ADRIANI. Good morning. It is a pleasure to be here once again. As you can see from my statement I was here November 24, 1970, to discuss the same subject we are discussing today, but from a little different point of view.

Senator NELSON. For purposes of the record, Dr. Adriani, would you give a little bit of your background, so that those who read these hearings will know your background, including your service as chairman of the American Medical Association Council on Drugs?

Dr. ADRIANI. I am emeritus professor of surgery (anesthesiology) at Tulane University School of Medicine. I am still active in the departments of pharmacology and anesthesiology at the Louisiana State University School of Medicine and a consultant in anesthesiology and pharmacology in the Department of Health and Human Resources of Louisiana and consultant in various hospitals in New Orleans and still on the staff at the Charity Hospital.

I have appeared before this committee in the past. On one occasion I appeared in my own behalf, while I was chairman of the council of drugs of the AMA. At that time we discussed various things. One of the things we discussed at that time was the publication of a drug compendium. You were very much interested in the publication of such a book on drug information—you had the feeling that doctors did not get enough drug information; the schools did not have enough input and doctors were using drugs empirically.

I agree with you on that. We still have that problem, although it seems to be correcting itself. I am still active, not retired, but I have given up the chairmanships of the various departments I held at Tulane, LSU and Charity. I was the chairman of the anesthesia department at Tulane, at LSU and chief of the anesthesiology service at Charity Hospital for 35 years.

I am also on two advisory panels of the Food and Drug Administration; one on the evaluation of topical analgesic drugs and the other on oral cavity preparations.

As I said before, my statement starts off with the fact that I was here in 1970. At that time, we were talking about analgesics, particularly propoxyphene. As I recall it the question that was at issue was the matter of the Government, particularly the Armed Forces, spending a premium amount of money for Darvon when other drugs that were more effective could have been used and were much less expensive. The issue of lack of effectiveness was fairly well emphasized.

Now, my experience with Darvon goes back when they first began to evaluate it, as an investigational drug. I could not see from the